Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.34 |
| ▸ | EDNRB | P24530 | 6/20 | 0.34 |
| ▸ | EDNRA | P25101 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047827 | 0.89 | MC4R (0.35) | TSPO | |
| SCHEMBL4752874 | 0.86 | TSPO (0.34) | TSPOEDNRBEDNRADRD4APLNR | |
| SCHEMBL4700037 | 0.85 | TLR9 (0.33) | TSPOEDNRBEDNRADRD4APLNR | |
| SCHEMBL6047776 | 0.83 | MTNR1A (0.43) | TSPO | |
| SCHEMBL6047829 | 0.82 | MTNR1A (0.42) | TSPOEDNRBEDNRA | |
| SCHEMBL6047837 | 0.81 | CYP1A2 (0.34) | TSPOSIGMAR1 | |
| SCHEMBL4696582 | 0.80 | ROCK1 (0.38) | TSPO | |
| SCHEMBL6047808 | 0.80 | KDM4E (0.43) | TSPO | |
| SCHEMBL6047770 | 0.78 | MC4R (0.34) | TSPO | |
| SCHEMBL6047795 | 0.77 | MTNR1A (0.45) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | TSPO 491/4885EDNRB 124/4885EDNRA 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.